Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Research groups

Adam Khan-Qureshi

MRC-DTP DPhil Candidate

Douglas Group

Biography

I graduated in 2022 from the University of Warwick for a MBio in Biochemistry with Industrial Placement. During my undergraduate studies I conducted a three-month research project in the Frigerio Group (2021, University of Warwick) investigating the role of pathogen effectors on endoplasmic reticulum morphology. During my final year, I was based at AstraZeneca (Cambridge, 2021-22) in the Cell Line Development & Engineering department, researching the mechanisms of low productivity and aggregation of a novel bispecific fragment fusion antibody. My particular interests lie in protein biochemistry and the arms race between host and pathogen, and therefore for my DPhil I decided to focus on vaccinology and virology. 

My current work in the Douglas Group focuses on pre-clinical development of vaccines against the Epstein Barr Virus (EBV), with specific interest in targeting the viral fusion machinery. This research involves using molecular biology tools and some structural biology techniques to interrogate the mechanisms by which these proteins are implicated in the viral-host arms race.